InnoCare announced first subject dosed
InnoCare has announced that the first subject has been dosed in its clinical trial of its novel targeted protein degrader ICP-490 in China. The company focuses on the treatment of cancer and autoimmune diseases, with this candidate aiming to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL).
The drug has been developed on InnoCare’s molecular glue platform, and aims to overcome acquired resistance against earlier generation CRBN modulators. According to the company’s press release: “Synergizing and enhancing efficacy of monoclonal antibodies (mAbs), ICP-490 provides strong rationale of synergistic combinations in the clinic, and demonstrates immense potential in the haematology field.”
It is hoped that ICP-490 will demonstrate anti-tumour effects in various MM and diffuse large B-cell lymphoma (DLBCL). MM currently accounts for 10% of blood tumours, while NHL is the most common haematological malignancy in the world and is among the top ten most common malignant tumours in China, so new and effective treatments are always well-received.
Dr Jasmine Cui, the co-founder, chairwoman and chief executive officer of InnoCare, commented: “ICP-490 is a highly potent next generation CRBN Modulator. Developed for the treatment of multi-indications, it has the potential to become a blockbuster in our blood tumour pipeline. We will accelerate its clinical development and explore single or combined therapies, expecting to benefit the blood tumour patients early.”